Cargando…

The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers

Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Andrew C., Walker, Richard, Hamilton, Melanie, Garrill, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685506/
https://www.ncbi.nlm.nih.gov/pubmed/26372466
http://dx.doi.org/10.1089/jamp.2015.1223
_version_ 1782406325946286080
author Grant, Andrew C.
Walker, Richard
Hamilton, Melanie
Garrill, Karl
author_facet Grant, Andrew C.
Walker, Richard
Hamilton, Melanie
Garrill, Karl
author_sort Grant, Andrew C.
collection PubMed
description Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was developed for the delivery of once-daily therapies for the treatment of asthma and chronic obstructive pulmonary disease. It has moderate resistance to airflow and can hold one or two blister strips, with each blister containing a sealed single dose of medication. Monotherapies can be delivered by the single-strip configuration and, in the two-strip configuration, one dose from each strip can be aerosolized simultaneously to allow combination therapies to be delivered, which enables the formulations for each product to be developed individually, since they are stored separately until the point of administration. There are three principal operating steps to administer a dose: open, inhale, close. This article summarizes the design, functionality, and in vitro dose-delivery characteristics of the ELLIPTA inhaler, and describes the results of human factors validation tests, designed to assess the performance of critical tasks required to use the inhaler. Results from the in vitro studies indicate that the ELLIPTA inhaler performs consistently with respect to in vitro dose delivery characteristics at a range of flow rates that can be achieved by the target population (≥30 L/min) and over its 30-day in-use life. Data from the human factors validation tests demonstrated that almost all participants (≥97%) were able to complete each of the steps required to prepare a dose for inhalation without error. Overall, the ELLIPTA inhaler has a versatile single- or two-strip design that allows it to be used for the delivery of a range of treatment options. It also improves patient ease-of-use when compared with the DISKUS(®) DPI.
format Online
Article
Text
id pubmed-4685506
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-46855062015-12-22 The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers Grant, Andrew C. Walker, Richard Hamilton, Melanie Garrill, Karl J Aerosol Med Pulm Drug Deliv Original Research Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was developed for the delivery of once-daily therapies for the treatment of asthma and chronic obstructive pulmonary disease. It has moderate resistance to airflow and can hold one or two blister strips, with each blister containing a sealed single dose of medication. Monotherapies can be delivered by the single-strip configuration and, in the two-strip configuration, one dose from each strip can be aerosolized simultaneously to allow combination therapies to be delivered, which enables the formulations for each product to be developed individually, since they are stored separately until the point of administration. There are three principal operating steps to administer a dose: open, inhale, close. This article summarizes the design, functionality, and in vitro dose-delivery characteristics of the ELLIPTA inhaler, and describes the results of human factors validation tests, designed to assess the performance of critical tasks required to use the inhaler. Results from the in vitro studies indicate that the ELLIPTA inhaler performs consistently with respect to in vitro dose delivery characteristics at a range of flow rates that can be achieved by the target population (≥30 L/min) and over its 30-day in-use life. Data from the human factors validation tests demonstrated that almost all participants (≥97%) were able to complete each of the steps required to prepare a dose for inhalation without error. Overall, the ELLIPTA inhaler has a versatile single- or two-strip design that allows it to be used for the delivery of a range of treatment options. It also improves patient ease-of-use when compared with the DISKUS(®) DPI. Mary Ann Liebert, Inc. 2015-12-01 /pmc/articles/PMC4685506/ /pubmed/26372466 http://dx.doi.org/10.1089/jamp.2015.1223 Text en © The Author(s) 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Grant, Andrew C.
Walker, Richard
Hamilton, Melanie
Garrill, Karl
The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title_full The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title_fullStr The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title_full_unstemmed The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title_short The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
title_sort ellipta(®) dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685506/
https://www.ncbi.nlm.nih.gov/pubmed/26372466
http://dx.doi.org/10.1089/jamp.2015.1223
work_keys_str_mv AT grantandrewc theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT walkerrichard theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT hamiltonmelanie theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT garrillkarl theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT grantandrewc elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT walkerrichard elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT hamiltonmelanie elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers
AT garrillkarl elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers